ECSP10010150A - Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida - Google Patents

Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Info

Publication number
ECSP10010150A
ECSP10010150A EC2010010150A ECSP10010150A ECSP10010150A EC SP10010150 A ECSP10010150 A EC SP10010150A EC 2010010150 A EC2010010150 A EC 2010010150A EC SP10010150 A ECSP10010150 A EC SP10010150A EC SP10010150 A ECSP10010150 A EC SP10010150A
Authority
EC
Ecuador
Prior art keywords
benzimidazol
carboxamida
pirrolidin
methyl
crystal form
Prior art date
Application number
EC2010010150A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence Kolaczkowski
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010150(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP10010150A publication Critical patent/ECSP10010150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2010010150A 2007-10-12 2010-05-03 Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida ECSP10010150A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
ECSP10010150A true ECSP10010150A (es) 2010-06-29

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010150A ECSP10010150A (es) 2007-10-12 2010-05-03 Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (28)

Country Link
US (4) US8372987B2 (enExample)
EP (2) EP2212327A1 (enExample)
JP (4) JP2011500589A (enExample)
KR (2) KR20160039312A (enExample)
CN (2) CN105367554A (enExample)
AU (1) AU2008310781B2 (enExample)
BR (1) BRPI0816221A8 (enExample)
CA (2) CA3006332A1 (enExample)
CO (1) CO6280493A2 (enExample)
CR (1) CR11368A (enExample)
DK (1) DK2722046T3 (enExample)
DO (1) DOP2010000099A (enExample)
EC (1) ECSP10010150A (enExample)
ES (1) ES2620299T3 (enExample)
GT (1) GT201000080A (enExample)
MX (1) MX350019B (enExample)
MY (1) MY156691A (enExample)
NZ (1) NZ583209A (enExample)
PA (1) PA8798401A1 (enExample)
PH (1) PH12012501636A1 (enExample)
PL (1) PL2722046T3 (enExample)
PT (1) PT2722046T (enExample)
RU (2) RU2476434C2 (enExample)
SG (1) SG185297A1 (enExample)
TW (1) TWI422588B (enExample)
UA (2) UA101961C2 (enExample)
WO (1) WO2009049111A1 (enExample)
ZA (1) ZA201002090B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562081T3 (es) 2007-10-12 2016-03-02 Abbvie Bahamas Ltd. Forma cristalina 2 de 2-((R)-2-metilpirrolidin-2-il)-1H-bencimidazol-4-carboxamida
PL2722046T3 (pl) 2007-10-12 2017-06-30 Abbvie Ireland Unlimited Company Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
WO2017152846A1 (zh) * 2016-03-09 2017-09-14 苏州晶云药物科技有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
ES2562081T3 (es) * 2007-10-12 2016-03-02 Abbvie Bahamas Ltd. Forma cristalina 2 de 2-((R)-2-metilpirrolidin-2-il)-1H-bencimidazol-4-carboxamida
PL2722046T3 (pl) 2007-10-12 2017-06-30 Abbvie Ireland Unlimited Company Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu

Also Published As

Publication number Publication date
US20140024838A1 (en) 2014-01-23
US8835647B2 (en) 2014-09-16
TWI422588B (zh) 2014-01-11
BRPI0816221A2 (pt) 2015-06-16
CA3006332A1 (en) 2009-04-16
GT201000080A (es) 2012-04-03
US8372987B2 (en) 2013-02-12
UA113277C2 (xx) 2017-01-10
MX350019B (es) 2016-12-09
KR20160039312A (ko) 2016-04-08
CN105367554A (zh) 2016-03-02
BRPI0816221A8 (pt) 2015-09-22
RU2012147692A (ru) 2014-05-20
PA8798401A1 (es) 2009-05-15
NZ583209A (en) 2012-06-29
US20130123317A1 (en) 2013-05-16
US20150148392A1 (en) 2015-05-28
ES2620299T3 (es) 2017-06-28
WO2009049111A1 (en) 2009-04-16
RU2476434C2 (ru) 2013-02-27
CA2696424A1 (en) 2009-04-16
AU2008310781B2 (en) 2013-03-28
PT2722046T (pt) 2017-03-15
JP2019001811A (ja) 2019-01-10
SG185297A1 (en) 2012-11-29
KR20100090769A (ko) 2010-08-17
US9580410B2 (en) 2017-02-28
CN101821270A (zh) 2010-09-01
UA101961C2 (xx) 2013-05-27
TW200932747A (en) 2009-08-01
US20090099245A1 (en) 2009-04-16
ZA201002090B (en) 2011-11-30
PL2722046T3 (pl) 2017-06-30
JP2014237659A (ja) 2014-12-18
CA2696424C (en) 2018-07-10
CR11368A (es) 2010-10-25
MX2010003772A (es) 2010-04-21
DOP2010000099A (es) 2017-04-30
RU2010116397A (ru) 2011-11-20
EP2722046A1 (en) 2014-04-23
JP2011500589A (ja) 2011-01-06
CO6280493A2 (es) 2011-05-20
EP2722046B1 (en) 2016-12-21
MY156691A (en) 2016-03-15
EP2212327A1 (en) 2010-08-04
PH12012501636A1 (en) 2015-07-10
JP2017071618A (ja) 2017-04-13
DK2722046T3 (en) 2017-03-20
AU2008310781A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
ECSP10010150A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares